Azure Health Technology Limited is an Australian public biotechnology company which is listed on the Australian Stock Exchange (ASX:AZT). Currently, AZT is undertaking an acquisition of an Australian unlisted public biotechnology company, Invictus BioPharma Ltd, a General Public Offer and seeking to have its shares requoted on the ASX in April 2020.
On completion of these transactions, AZT will be developing and commercialising novel nutraceuticals and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness (DOMS), muscle recovery after exercise, maintenance of peak muscle power, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia and diabetes.
AZT will own and control patent and other intellectual property rights for novel approaches to delivering tocotrienols directly to the target tissues. The Company will have a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.
The information provided on this web site assumes the successful completion of the above-mentioned transactions, i.e., that AZT has acquired Invictus BioPharma Ltd.
To obtain more information about the General Public Offer please click here to view the Prospectus.
To obtain an Application Form for the General Public Offer after reading the Prospectus, please click here.
Mr Stuart Roberts of Pitt Street Research has released an analyst report on AZT and if you want to read this please click here.